| Business Summary | | Triangle
Pharmaceuticals,
Inc.
develops
new
drug
candidates
primarily
in
the
antiviral
area,
with
a
particular
focus
on
therapies
for
HIV,
including
AIDS,
and
the
hepatitis
B
virus.
The
Company
has
an
existing
portfolio
of
six
licensed
drug
candidates
in
clinical
trials
and
several
drug
candidates
that
are
in
a
pre-clinical
stage
or
for
which
it
has
an
option
to
acquire
a
license.
Its
portfolio
include
Coviracil
(emtricitabine),
a
nucleoside
analogue
that
has
been
shown
to
be
a
potent
inhibitor
of
HIV
and
hepatitis
B
virus
replication
in
laboratory
studies;
Coactinon
(emivirine),
a
non-nucleoside
reverse
transcriptase
inhibitor;
DAPD,
a
purine
dioxolane
nucleosides
currently
in
development
for
the
treatment
of
viral
diseases;
Mozenavir
dimesylate,
a
potent,
selective
inhibitor
of
the
HIV-1
protease;
clevudine,
shown
to
be
a
potent
inhibitor
of
hepatitis
B
virus
replication
in
laboratory
studies;
and
immunostimulatory
sequences
candidates
for
hepatitis
B. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | VIRS
is
a
pharmaceutical
company
engaged
in
the
development
of
new
drug
candidates
primarily
in
the
anti-viral
area,
with
a
particular
focus
on
therapies
for
HIV.
For
the
six
months
ended
6/30/01,
revenues
fell
8%
to
$3.5
million.
Net
loss
fell
24%
to
$44
million.
Results
reflect
an
extension
of
the
development
period
for
which
collaborative
revenues
are
amortized,
offset
by
lower
manufacturing
costs
and
the
absence
of
a
$5.4
million
purchased
research
and
development
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY1999 Pay | |
| David Barry, M.D., 56 Chairman,
CEO | $447K | Chris Rallis, J.D., 46 Pres,
COO, Director | 495K | Robert Amundsen, Jr. Exec.
VP, CFO | -- | Andrew Finkle Exec.
VP, Gen. Counsel, Sec. | -- | Paul Dreyer Exec. VP, Commercial Operations | -- | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|